全文获取类型
收费全文 | 7421篇 |
免费 | 886篇 |
国内免费 | 431篇 |
专业分类
耳鼻咽喉 | 84篇 |
儿科学 | 42篇 |
妇产科学 | 63篇 |
基础医学 | 507篇 |
口腔科学 | 165篇 |
临床医学 | 1188篇 |
内科学 | 849篇 |
皮肤病学 | 71篇 |
神经病学 | 345篇 |
特种医学 | 252篇 |
外国民族医学 | 1篇 |
外科学 | 964篇 |
综合类 | 1480篇 |
预防医学 | 398篇 |
眼科学 | 679篇 |
药学 | 607篇 |
6篇 | |
中国医学 | 133篇 |
肿瘤学 | 904篇 |
出版年
2024年 | 24篇 |
2023年 | 239篇 |
2022年 | 390篇 |
2021年 | 422篇 |
2020年 | 376篇 |
2019年 | 233篇 |
2018年 | 204篇 |
2017年 | 161篇 |
2016年 | 247篇 |
2015年 | 388篇 |
2014年 | 820篇 |
2013年 | 666篇 |
2012年 | 937篇 |
2011年 | 865篇 |
2010年 | 583篇 |
2009年 | 466篇 |
2008年 | 374篇 |
2007年 | 215篇 |
2006年 | 168篇 |
2005年 | 188篇 |
2004年 | 133篇 |
2003年 | 126篇 |
2002年 | 122篇 |
2001年 | 89篇 |
2000年 | 42篇 |
1999年 | 40篇 |
1998年 | 19篇 |
1997年 | 23篇 |
1996年 | 20篇 |
1995年 | 17篇 |
1994年 | 13篇 |
1993年 | 7篇 |
1992年 | 5篇 |
1991年 | 8篇 |
1990年 | 5篇 |
1989年 | 9篇 |
1986年 | 4篇 |
1969年 | 4篇 |
1965年 | 5篇 |
1963年 | 3篇 |
1962年 | 3篇 |
1961年 | 3篇 |
1960年 | 3篇 |
1959年 | 4篇 |
1958年 | 3篇 |
1957年 | 3篇 |
1948年 | 8篇 |
1944年 | 3篇 |
1939年 | 4篇 |
1932年 | 4篇 |
排序方式: 共有8738条查询结果,搜索用时 156 毫秒
1.
2.
3.
《International journal of oral and maxillofacial surgery》2020,49(12):1599-1604
Helicobacter pylori is an established cause of gastric ulcers. Its role in causing recurrent aphthous stomatitis (RAS) remains controversial. Fifty-two RAS patients and 52 sex-matched controls were recruited in this case–control study. All subjects were screened for hematinic deficiencies and H. pylori. The latter was assessed quantitatively using the 14C-urea breath test. The χ2 test and Wilcoxon signed ranks test were used to compare H. pylori and hematinic indices between cases and controls, while conditional logistic regression was used to assess the associations between the occurrence of RAS and independent factors. H. pylori was positive in 56.7% of the overall sample, with no difference between RAS patients (50.8%) and controls (49.2%) (P = 0.843). The median H. pylori and haematological indices values did not show any association with ulcer diameter, number, or frequency. Interestingly, gastric hyperacidity was significantly associated with RAS, and this association was independent from tobacco smoking, alcohol drinking, and H. pylori (odds ratio 14.99, 95% confidence interval 2.47–90.95; P = 0.003). This study found no association between H. pylori and RAS. The association between RAS and gastric hyperacidity suggests that gastric refluxate, not H. pylori, has an effect on the oral mucosa that favours an ulcerative change. 相似文献
4.
目的:探讨单孔胸腔镜下肺癌手术术后胸腔引流时间的影响因素。方法:本研究采用回顾性分析方法,回顾我院2018年01月至2019年12月原发性肺癌患者经单孔胸腔镜手术治疗的病例199例。按照术后胸腔引流时间分为两组,Ⅰ组(术后胸腔引流时间<5天)和Ⅱ组(术后胸腔引流时间≥5天)。对于影响术后胸腔引流时间的可能因素在两组间先采用单因素分析的方法筛选,再将筛选出来的对术后胸腔引流时间可能有意义的影响因素进行二项Logistic多因素回归分析。结果:经单因素分析及二项Logistic多因素回归分析结果显示:年龄≥60岁、手术部位、肺段切除术、胸膜粘连、手术时间≥180 min、术后早期下床活动是术后胸腔引流时间的独立影响因素(P<0.05)。结论:对于具有多个延长术后胸腔引流时间的独立影响因素的患者,应制定个体化管理方案,尽可能减少术后胸腔引流时间,减少住院天数,加快患者康复。 相似文献
5.
6.
7.
8.
9.
《Clinical colorectal cancer》2020,19(4):285-290
BackgroundFOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC). Our aim was to investigate efficacy and tolerability of this combination in the first line.Patients and MethodsPatients with untreated documented mCRC received aflibercept plus FOLFIRI every 14 days until progression or unacceptable toxicity in an open, phase II single-arm, multicenter trial. The primary endpoint was the 6-month PFS rate. Secondary endpoints were OS and tolerability. A 2-step Simon design was used with H0: 55% and H1= 75%. Data were analyzed in intention to treat.ResultsForty-one patients were included, and 40 were analyzed (1 consent withdrawal) in 9 French centers between October 2014 and February 2017. The median age was 65 years (range, 46-81 years), 55% had ≥ 2 metastatic sites, and 50% and 15% had RAS and BRAF mutations, respectively. Twenty-two (54.5%; 95% confidence interval, 38.9%-68.5%) patients were alive and non-progressive at 6 months. FOLFIRI + aflibercept was considered ineffective, resulting in the cessation of inclusions. The median follow-up was 34 months. The overall response rate was 55%, and the disease control rate was 80%. The median duration of treatment was 5.3 months; the median PFS and OS were 8.2 and 18.6 months, respectively. Grade 3 to 4 adverse events were mainly gastrointestinal (47.5%) and vascular (32.5%). Of the patients, 87.5% had at least 1 dose modification.ConclusionAlthough the primary objective was not met, first-line FOLFIRI + aflibercept for mCRC leads to median PFS and OS close to those reported with classical doublet and targeted agents, but with significant toxicities needing dose reduction. 相似文献
10.